Clinical trial Recruiting at 1 site Interventional Ages Any age to 18

Local botulinum toxin‑A injections for children with dysfunctional voiding or persistent bedwetting

Official title: Evaluation of Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis

Run by Tanta University · NCT07523477 · Data updated 2026-11-12

This will try a local injection of botulinum toxin‑A to see if it helps children with dysfunctional voiding or persistent nighttime bedwetting who haven't improved with standard treatments.

More Local Injection trials

Quick facts

Study typeInterventional
AgesAny age to 18 Years
SexAll
Enrollment64 (estimated)
SponsorTanta University
Academic / other
Locations1 site (Tanta, El-Gharbia)
StatusRecruiting
StartedJune 1, 2025
Main results expectedDecember 1, 2026
Study endsDecember 1, 2026
Registry record updatedApril 13, 2026
Trial IDNCT07523477 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children under 18 with dysfunctional voiding or refractory nocturnal enuresis who have not improved with standard treatments and who are medically fit for anesthesia may be eligible.

Probably not a fit

Children with bleeding disorders, neuromuscular diseases (e.g., myasthenia gravis), active urinary tract infection, or those unfit for anesthesia are excluded and unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional protocol delivers botulinum toxin‑A injections to the lower urinary tract of children with dysfunctional voiding or refractory monosymptomatic nocturnal enuresis who have not responded to conventional therapy. The procedure is performed under anesthesia and excludes children with bleeding disorders, neuromuscular disease, active urinary infection, or those unfit for anesthesia. Botulinum toxin‑A acts by inhibiting neurotransmitter release and modulating sensory receptors in the bladder and urethral sphincter to reduce involuntary contractions and improve emptying. The trial is conducted at Tanta University in Tanta, El‑Gharbia, Egypt.

Why it matters

Potential benefit: If successful, the injections could reduce involuntary sphincter contractions and bedwetting episodes, lowering post‑void residuals and improving daytime and nighttime urinary control.

How similar studies have gone: Botulinum toxin‑A has shown symptomatic benefit in other pediatric bladder and sphincter dysfunction studies, though data specifically for refractory nocturnal enuresis are more limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Children \< 18 years.
* Both sexes.
* Patients with refractory nocturnal enuresis or dysfunctional voiding who are not responding to the traditional treatment.

Exclusion Criteria:

* Bleeding disorders.
* Neuromusclar disorder(e.g.,Myasthenia gravis).
* Patients who are not fit for anaesthesia.
* Active urinary tract infection (UTI).

Where it's running

  • Tanta University
    Tanta, El-Gharbia, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.